|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-3-2
|
|
pubmed:abstractText |
Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1355-7
|
|
pubmed:meshHeading |
pubmed-meshheading:20179241-Animals,
pubmed-meshheading:20179241-Antineoplastic Agents,
pubmed-meshheading:20179241-Breast Neoplasms,
pubmed-meshheading:20179241-Clinical Trials as Topic,
pubmed-meshheading:20179241-Drug Resistance, Neoplasm,
pubmed-meshheading:20179241-Female,
pubmed-meshheading:20179241-Humans,
pubmed-meshheading:20179241-Quinazolines,
pubmed-meshheading:20179241-Receptor, erbB-2,
pubmed-meshheading:20179241-Receptor Cross-Talk,
pubmed-meshheading:20179241-Receptors, Estrogen
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Does lapatinib work against HER2-negative breast cancers?
|
|
pubmed:affiliation |
Departments of Medicine, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
